bipolar I disorder, acute mania
Mental health · 2005–2010
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| quetiapine Adjunctive therapy to mood stabilisers for up to 6 months for an episode of acute mania associated with bipolar I disorder. | Nov 2010 | Recommended | no section in document |
| risperidone Adjunctive therapy to mood stabilisers for the treatment of an episode of acute mania associated with bipolar I disorder. | Nov 2005 | Recommended with restriction | no section in document |
| risperidone Adjunctive therapy to mood stabilisers for the treatment of an episode of acute mania associated with bipolar I disorder. | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$41M in government benefit over 2024–25, across 1,443,883 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| risperidone | $21.3M |
| quetiapine | $19.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.